Home > Insider Trading > Filing (0000899243-18-017779)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1731831	Eidos Therapeutics Inc.	EIDX	Pharmaceutical Preparations (2834)	463733671

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1742485	Neil Kumar	C/O Eidos Therapeutics, Inc. 101 Montgomery Street, Suite 2550 San Francisco CA 94104	Chief Executive Officer	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-06-22	18,826,417	$0.00	18,826,417	No	4	C	Indirect	See footnote
Common Stock	Disposition	2018-06-22	211,762	$17.00	18,614,655	No	4	F	Indirect	See footnote
Common Stock	Acquisiton	2018-06-22	1,000,000	$17.00	19,614,655	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	F	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Series B Preferred Stock	Warrants	Disposition	2018-06-22	332,262	$0.00	332,262	$10.83
Common Stock	Series B Convertible Preferred Stock	Acquisiton	2018-06-22	332,262	$0.00	397,385	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2018-06-22	2,909,029	$0.00	3,479,198	$0.00
Common Stock	Series Seed Preferred Stock	Disposition	2018-06-22	12,832,123	$0.00	15,347,219	$0.00

Remaning Holdings	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	No	4	X	Indirect
2,909,029	No	4	X	Indirect
0	No	4	C	Indirect
0	No	4	C	Indirect

Footnotes

Immediately prior to completion of the Issuer's initial public offering, the warrants were automatically exercised for shares of Series B Preferred Stock and such shares acquired were automatically converted into shares of the Issuer's Common Stock on a 1 to 1.196 basis, net of shares of Common Stock withheld by the Issuer to cover the exercise price, resulting in the issuance of 185,623 shares of Common Stock.
The shares are owned by BridgeBio Pharma LLC. The Reporting Person is the chief executive officer and a managing member of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.
Upon closing of the Issuer's initial public offering, the preferred stock automatically converted into the Issuer's Common Stock on a 1 to 1.196 basis.